These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 34199053)

  • 1. Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.
    Park JY; Choi SH; Chung JW; Hwang MH; Kim MC
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34199053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
    Lim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim SH; Kim CK; Kim T; Choo EJ; Moon JE; Yun J; Park SK
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea.
    Song JE; Oh GB; Park HK; Lee SS; Kwak YG
    Infect Chemother; 2021 Sep; 53(3):557-561. PubMed ID: 34405593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
    Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers.
    Lim S; Lee Y; Kim DW; Park WS; Yoon JH; Lee JY
    Infect Chemother; 2022 Mar; 54(1):140-152. PubMed ID: 35384425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers.
    Kale P; Gupta E; Bihari C; Patel N; Rooge S; Pandey A; Bajpai M; Khillan V; Chattopadhyay P; Devi P; Maurya R; Jha N; Mehta P; Kumar M; Sharma P; Saifi S; Swaminathan A; Alam S; Uppili B; Faruq M; Agrawal A; Pandey R; Sarin SK
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events.
    Terpos E; Politou M; Ntanasis-Stathopoulos I; Karalis V; Merkouri E; Fotiou D; Gavriatopoulou M; Malandrakis P; Kastritis E; Trougakos IP; Dimopoulos MA
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
    Devi LS; Sardar M; Sharma M; Khandait M
    Int J Microbiol; 2022; 2022():4729844. PubMed ID: 35685779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
    Jeon M; Kim J; Oh CE; Lee JY
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of ChAdOx1 nCoV-19 (Covishield
    Verma A; Goel A; Katiyar H; Tiwari P; Mayank ; Sana A; Khetan D; Bhadauria DS; Raja A; Khokher N; Shalimar ; Singh RK; Aggarwal A
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples.
    Chan KH; Leung KY; Zhang RR; Liu D; Fan Y; Chen H; Yuen KY; Hung IF
    Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.
    Park MJ; Choi YJ; Choi S
    J Korean Med Sci; 2021 Jul; 36(27):e196. PubMed ID: 34254475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization Assessments Reveal High Cardiothoracic Ratio and Old Age as Independent Predictors of Low Neutralizing Antibody Titers in Hemodialysis Patients Receiving a Single Dose of COVID-19 Vaccine.
    Chen CY; Liu KT; Shih SR; Ye JJ; Chen YT; Pan HC; Hsu HJ; Sun CY; Lee CC; Wu CY; Lai CC; Wu IW
    J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.
    Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK
    Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
    Wi YM; Kim SH; Peck KR
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
    Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
    Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.